TE Connectivity designs, develops, and manufactures microfluidic technologies for advanced, high throughput DNA sequencing devices and platforms.
In addition to its uses for diagnosis, prognosis, and biomarker discoveries, Next Generation Sequencing (NGS) is used to understand genomic, transcriptomic, and epigenomic alterations. It allows for the identification of genetic variations that cause various diseases or disorders like cancers. NGS is the backbone of personalized medicine, as it provides high specificity and sensitivity of genome isolation and enrichment. These techniques unlock rapid forms of diagnosis, prognosis, and biomarker discoveries for diseases. Clinicians can get more accurate information about disease characteristics using automated molecular technologies such as NGS.
The TE Connectivity´s IVD Solutions team can accelerate your NGS project by leveraging microfluidic technology to gain improved control over fluid handling and microenvironment conditions. The microfluidic platform benefits from faster analysis on a single consumable device and multiplexing to enhance throughput. Our expertise in the design, development, and production of NGS microfluidics spans any application, from targeted genome sequencing to viral susceptibility analysis, cancer sequencing, and more.
Our NGS technologies form the foundation of personalized medicine, with targeted sequencing allowing clinicians to rapidly investigate genomes related to diseases, disorders, or pathogens. Rely on TE to develop and produce
standardized and proprietary-adjacent microfluidics for NGS and other molecular diagnostic assays with manufacturability and reliability.
Personalized Medicine Facilitation
Next generation sequencing allows for the identification of genetic variations that
cause various diseases or disorders like cancers. It is the backbone of personalized medicine, as it provides high specificity and sensitivity of genome isolation and enrichment. The use of NGS can unlock rapid forms of diagnosis, prognosis, and biomarker discoveries for diseases. Clinicians can receive improved point-of-care (POC) diagnostics and information about disease characteristics with automated molecular technologies such as NGS.
Proven Expertise, From Concept to Market
Microfluidic Applications for NGS
TE designs, develops, and manufactures microfluidic technologies used in advanced DNA sequencing devices and platforms. Typical library preparation methods require large amounts of input DNA and complicated manual processes. Our microfluidic devices automate multiple steps in the assay process, from sample collection and preparation through to the final readout of the gene sequence. The result is improved throughput, cost-effectiveness, and automation over traditional sequencing, in addition to improved understanding of molecular properties and biology. Another benefit us that microfluidic devices allow for smaller volumes of samples and reagents, further reducing final costs.
- Isolation and Enrichment
- Automated Sample Preparation
- Sequencing Library Preparation
- Droplet Generation
- Epigenetic Factor Analysis
- Single Cell Analysis
- Whole Genome Sequencing
- Targeted Sequencing
- RNA Sequencing
- Cancer Sequencing
- Novel Pathogen Identification
- Transcriptomic Sequencing
- Human Microbiome Research
- Susceptibility Analysis
TE provides end-to-end NGS solutions that automate, multiplex, and integrate with proprietary systems. Our chip designs are encapsulated entirely within the
device to speed output, lower costs, and minimize the potential for human error and contamination. For example, we can design microfluidic geometry that achieves the desired performance, flow conditions, and fluid properties while applying microfluidic droplet isolation techniques with PCR processes to increase target gene concentration. We also design microstructures and develop devices that can automate NGS workflows including template amplification, fragmentation, droplet generation, barcoding (unique tagging), PCR, and final read of the gene sequence.